**Sir**,

We read with great interest the online article by [@bib3] and congratulate the authors on completing this randomized phase II trial. This study concludes that free IGF-1 (fIGF-1) may contribute to the identification of a subset of NSCLC patients who would benefit from figitumumab therapy. They also showed that the plasma fIGF-1 levels were found to be associated with tumour vimentin expression (*P*=0.021) and are inversely associated with E-cadherin (*P*=0.152) in 45 out of 110 NSCLC patients. Therefore, investigation to verify whether there is a correlation in the appearance of the ligand and receptor in pretreatment samples was warranted, as the IGF-1 receptor (IGF-1R) expression was tightly regulated at multiple levels ([@bib2]).

We have recently investigated the expression of EMT-related molecules ([@bib7]) and IGF-1R ([@bib5]) in NSCLC patients who underwent curative surgery. We have analysed the correlation between EMT molecules and IGF-1R. In our study, tumour specimens were collected from 182 consecutive patients who underwent a complete resection for lung adenocarcinoma from 2003 to 2007 in our department. According to the pathological stage, 105 patients had tumours of stage IA, 39 IB, 13 IIA, 6 IIB, and 16 IIIA, and 3 patients had tumours of stage IIIB, as classified according to the new TMN (seventh edition) classification for lung cancer. We analysed the associations between the expression levels of IGF-1R, E-cadherin, *γ*-catenin, and vimentin in the primary lung adenocarcinoma by immunohistochemisty.

Positive expression of IGF-1R was detected in 43 (23.6%) of the 182 cases. The expression of E-cadherin, *γ*-catenin, and vimentin was detected in 94 (51.4%), 82 (40.4%), and 32 (17.5%) patients, respectively. The *χ*^2^-test demonstrated a significant association between the IGF-1R and E-cadherin expression (*P*=0.009) and the *γ*-catenin expression (*P*=0.020). In contrast, IGF-1R failed to show any association with vimentin (*P*=0.840). Furthermore, the multivariate logistic regression models indicated that the expression of E-cadherin was an independent predictor for positive IGF-1R expression (*P*=0.026), and *γ*-catenin had a borderline correlation (*P*=0.058). Therefore, there might be a negative feedback loop between these molecules ([@bib1]) or sophisticated changes in the physiological concentration of IGF-1R ([@bib6]) in the IGF/IGF-1R axis. In fact, IGF-1R-dependent adhesion was restored when both E-cadherin and IGF-1R were co-expressed in breast cancer cell *in vitro* ([@bib4]).

The IGF-1R pathway has also been shown to exhibit cross-talk with a number of other signalling pathways ([@bib8]). There were differences in the patient selection with regard to patients not to amenable to curative treatment between Gualberto\'s report and the curative subgroups in our analysis. A detailed examination of a prospective trial can produce new information about the relationships between IGF/IGF-1R and the EMT, and not only the IGF-related molecules, but also the EMT status, may be predictive for the response to IGF-1R-inhibitors.
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